The latest announcement is out from Psyence Group ( (TSE:PSYG) ).
Psyence Biomedical, an associate of Psyence Group, has appointed Dr. Albert P. Garcia-Romeu as the chair of its newly formed Scientific Advisory Board, enhancing its research capabilities in psilocybin-based treatments. Additionally, Psyence Group has settled a debt of C$120,000 by issuing shares, reflecting strategic financial management.
More about Psyence Group
Psyence Group is a life science biotechnology company listed on the Canadian Securities Exchange, focusing on natural psychedelics. Its associate, Psyence Biomedical, is the first life science biotechnology company on Nasdaq dedicated to developing botanical psilocybin-based psychedelic medicines for psychological trauma and mental health issues in palliative care.
YTD Price Performance: -33.33%
Average Trading Volume: 21,289
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: C$1.4M
For detailed information about PSYG stock, go to TipRanks’ Stock Analysis page.